Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, and engineered to enhance tumor targeting and improve persistence for sustained activity in the body. For more information, please visit the company’s website at www.nkartatx.com.
Location: United States, California, South San Francisco
Employees: 51-200
Total raised: $114M
Founded date: 2015
Investors 5
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Logos Capi... | logoscapit... |
| - | RA Capital... | racap.com |
| - | Life Scien... | lspvc.com |
| - | SR One | srone.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.09.2019 | Series B | $114M | - |
Mentions in press and media 9
| Date | Title | Description |
| 11.09.2019 | Biopharmaceutical Company Nkarta Therapeutics Raises $114 Million | Biopharmaceutical company Nkarta Therapeutics announced it has raised $114 million in Series B funding Nkarta Therapeutics — a biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer — recently ann... |
| 06.09.2019 | Nkarta Therapeutics Raises $114M in Series B Financing | Nkarta Therapeutics, a South San Francisco, Calif.–based biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight cancer, closed a $114m Series B financing. The round was led by new investor Samsara BioCap... |
| 05.09.2019 | Nkarta Therapeutics Lands $114M Series B | SOUTH SAN FRANCISCO, CA, Nkarta Therapeutics today announced that it has closed an oversubscribed $114 million Series B financing. >> Click here for more funding data on Nkarta Therapeutics >> To export Nkarta Therapeutics f... |
| 04.09.2019 | Nkarta nets $114M to push natural killer cell therapies into the clinic | Amgen Ventures and Deerfield Management chipped in to a $114 million series B round for Nkarta, which now has the runway to start clinical trials for its natural killer (NK) cell therapy, build a manufacturing site and advance its earlier-s... |
| 04.09.2019 | Nkarta nets $114M to push natural killer cell therapies into the clinic W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Amgen Ventures and Deerfield Management chipped in to a $114 million series B round for Nkarta, which now has the runway to start clinical trials for its natural killer (NK) cell therapy, build a manufacturing site and advance its earlier-s... |
| 30.07.2019 | Pharma leaders: support the social contract on drug prices | When I was 13 years old, my doctor told me I had Crohn’s disease, a painful gastrointestinal condition that swells the intestines and threatens the digestive tract. Breakthrough treatments like Remicade, Enbrel, and Humira were still decade... |
| 14.12.2018 | Shinichi Tamura reclaims the throne at Sosei; Jeff Abbey exits Argos for Novadip; Frank Czerwiec is the new CMO at Goldfinch | → Jeff Abbey is jumping to the helm of Belgium’s Novadip Biosciences after leading Argos Therapeutics as president and CEO for the past eight years. Having led Novadip’s autologous cell therapy through a Phase I/IIa tria... |
| - | Nkarta’s natural killers flash potential as next-gen cell therapies for cancer | The first cell therapies for cancer employ T cells turned into targeted tumor fighters. Nkarta Therapeutics set out to show that a different type of cell can offer a new and potentially better twist on cancer immunotherapy. Now the biotech ... |
| - | Blocking FDA approval of abortion pill could stifle innovation in the biopharma industry, experts say | A complicated legal fight over the Food and Drug Administration’s approval of the abortion pill mifepristone could stifle innovation in the biopharma industry. If courts affirm U.S. District Judge Matthew Kacsmaryk’s decision to suspend the... |